Aclaris Therapeutics (ACRS) Competitors $2.09 +0.28 (+15.47%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ACRS vs. SIGA, PRTC, ALT, XERS, RGNX, ALEC, AVXL, BMEA, TERN, and CMPSShould you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include SIGA Technologies (SIGA), PureTech Health (PRTC), Altimmune (ALT), Xeris Biopharma (XERS), REGENXBIO (RGNX), Alector (ALEC), Anavex Life Sciences (AVXL), Biomea Fusion (BMEA), Terns Pharmaceuticals (TERN), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry. Aclaris Therapeutics vs. SIGA Technologies PureTech Health Altimmune Xeris Biopharma REGENXBIO Alector Anavex Life Sciences Biomea Fusion Terns Pharmaceuticals COMPASS Pathways SIGA Technologies (NASDAQ:SIGA) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends. Do institutionals & insiders have more ownership in SIGA or ACRS? 55.4% of SIGA Technologies shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 1.5% of SIGA Technologies shares are held by insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is SIGA or ACRS more profitable? SIGA Technologies has a net margin of 48.55% compared to Aclaris Therapeutics' net margin of -183.28%. SIGA Technologies' return on equity of 51.40% beat Aclaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SIGA Technologies48.55% 51.40% 39.58% Aclaris Therapeutics -183.28%-53.18%-41.74% Does the MarketBeat Community believe in SIGA or ACRS? Aclaris Therapeutics received 372 more outperform votes than SIGA Technologies when rated by MarketBeat users. Likewise, 66.49% of users gave Aclaris Therapeutics an outperform vote while only 23.81% of users gave SIGA Technologies an outperform vote. CompanyUnderperformOutperformSIGA TechnologiesOutperform Votes523.81% Underperform Votes1676.19% Aclaris TherapeuticsOutperform Votes37766.49% Underperform Votes19033.51% Do analysts prefer SIGA or ACRS? Aclaris Therapeutics has a consensus price target of $9.00, indicating a potential upside of 330.62%. Given Aclaris Therapeutics' higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than SIGA Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SIGA Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AAclaris Therapeutics 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better earnings and valuation, SIGA or ACRS? SIGA Technologies has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than SIGA Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSIGA Technologies$139.92M3.68$68.07M$1.176.16Aclaris Therapeutics$32.02M4.66-$88.48M-$0.82-2.55 Which has more volatility & risk, SIGA or ACRS? SIGA Technologies has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Does the media refer more to SIGA or ACRS? In the previous week, SIGA Technologies had 2 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 5 mentions for SIGA Technologies and 3 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 1.15 beat SIGA Technologies' score of 0.39 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SIGA Technologies 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aclaris Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySIGA Technologies beats Aclaris Therapeutics on 9 of the 16 factors compared between the two stocks. Ad Porter & CompanyWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRS vs. The Competition Export to ExcelMetricAclaris TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$149.11M$7.42B$5.54B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-2.559.93114.8115.14Price / Sales4.66396.631,495.55100.10Price / CashN/A47.3939.6734.08Price / Book0.945.324.665.02Net Income-$88.48M$153.56M$119.06M$225.46M7 Day Performance23.67%0.13%0.80%0.37%1 Month Performance78.63%15.23%5.65%3.57%1 Year Performance-58.78%41.14%36.75%29.43% Aclaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRSAclaris Therapeutics3.3165 of 5 stars$2.09+15.5%$9.00+330.6%-58.9%$149.11M$32.02M-2.5586Upcoming EarningsPositive NewsSIGASIGA Technologies3.0701 of 5 stars$6.77+2.7%N/A+42.5%$481.50M$172.96M5.7940Upcoming EarningsOptions VolumePRTCPureTech Health2.9111 of 5 stars$19.99-2.9%$45.00+125.1%+15.0%$478.36M$3.33M0.00100Positive NewsALTAltimmune1.8361 of 5 stars$6.69-1.0%$18.80+181.0%+175.1%$475.46M$430,000.00-4.1350Upcoming EarningsXERSXeris Biopharma3.8147 of 5 stars$3.20-1.2%$4.67+45.8%+72.7%$474.42M$181.41M-7.44290News CoveragePositive NewsRGNXREGENXBIO4.5128 of 5 stars$9.35-2.4%$35.45+279.2%-38.1%$460.54M$89.04M-1.77344Upcoming EarningsALECAlector4.1844 of 5 stars$4.76+3.5%$17.75+272.9%-8.1%$458.79M$55.28M-2.64270Upcoming EarningsPositive NewsAVXLAnavex Life Sciences3.4984 of 5 stars$5.24-1.7%$40.00+663.4%+21.6%$443.52MN/A-10.4840News CoverageBMEABiomea Fusion3.8084 of 5 stars$12.15+5.1%$29.40+142.0%-13.5%$436.73MN/A-3.1250Earnings ReportAnalyst ForecastAnalyst RevisionTERNTerns Pharmaceuticals4.6125 of 5 stars$6.67-1.2%$15.90+138.4%+32.2%$431.40M$1M-5.0540Analyst ForecastNews CoverageCMPSCOMPASS Pathways2.2856 of 5 stars$6.28-2.3%$47.40+654.8%-17.8%$429.43MN/A-2.72120Analyst ForecastShort Interest ↓News CoverageHigh Trading Volume Related Companies and Tools Related Companies SIGA Technologies Competitors PureTech Health Competitors Altimmune Competitors Xeris Biopharma Competitors REGENXBIO Competitors Alector Competitors Anavex Life Sciences Competitors Biomea Fusion Competitors Terns Pharmaceuticals Competitors COMPASS Pathways Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACRS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
